Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



Can stem cell therapy really treat MS?

MS sufferer Eric Thompson was able to rise from his wheelchair and walk just days after treatment with haematopoietic stem cells, according to a recent Daily Mail article. Unable to receive this aggressive treatment through the NHS, Thompson and his family raised £40,000 to undergo the treatment in Mexico.

The treatment Thompson received is called autologous haematopoietic stem cell transplantation (AHSCT). It involves extracting stem cells from the affected person’s bone marrow or blood. After the person has undergone intensive chemotherapy to wipe out their immune system, the stem cells are then reintroduced. It’s done to try to reboot the immune system. The use of intensive high-dose chemotherapy and the transplant process is an arduous procedure for this potent treatment.

According to Cancer Research UK donor stem cell transplants are used as a treatment for some types of cancer, including leukaemia, lymphoma and myeloma. However, it’s probably premature to recommend AHSCT as a treatment for MS.

Although it is not available on the NHS, the MS Society UK report a number of studies using the treatment for MS and they have shown promise, demonstrating a reduction in relapse for some people, stabilisation and even some reversal of disability. However, the MS Society also highlights that this is not the case for every MS patient. The treatment is aggressive and has significant risks.

Clinical trials

A number of AHSCT trials for MS are taking place, including the ASTIMS trial, published March 2015. This was conducted on 21 patients with relapsing remitting MS (individuals have distinct bouts of symptoms) or secondary progressive MS (disability builds up independent of relapses). Those having AHSCT showed a significantly greater reduction in relapses compared to patients having mitoxantrone.

Mitoxantrone is a type of chemotherapy treatment sometimes used as a disease-modifying therapy to reduce the number of relapses a person with MS might have. Researchers did, however, also state that some patients having AHSCT experienced severe adverse effects, such as thrombocytopenia (low platelet levels), neutropenia (low white blood cells), infection, and liver toxicity, with two of the participants suffering from life-threatening conditions including sepsis, severe infections and either a slow take-up of stem cells by the bone marrow (“engraftment”) or a complete failure to do so.

The UK is part of the international multi-centre (UK, US, Sweden and Brazil) randomised clinical trial MIST and several patients having AHSCT have shown particularly encouraging results. They reported improvement and reversal of MS symptoms, which were backed up by MRI results demonstrating no evidence of active disease. The full results of the trial are due to be published in 2017 and a lot of people are waiting with interest. The UK centre is the Royal Hallamshire Hospital in Sheffield and some of their trial patients were featured in a Panorama programme in January 2016.

Story Source: The above story is based on materials provided by THECONVERSATION
Note: Materials may be edited for content and length

Labels: ,

Go to Newer News Go to Older News